Share on StockTwits

Endologix (NASDAQ:ELGX) Director Thomas Wilder sold 3,500 shares of the stock in a transaction that occurred on Monday, August 4th. The shares were sold at an average price of $13.68, for a total value of $47,880.00. Following the sale, the director now directly owns 18,343 shares of the company’s stock, valued at approximately $250,932. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

A number of analysts have recently weighed in on ELGX shares. Analysts at JPMorgan Chase & Co. reiterated a “neutral” rating on shares of Endologix in a research note on Thursday, July 31st. They now have a $17.00 price target on the stock, up previously from $15.00. Separately, analysts at Credit Suisse initiated coverage on shares of Endologix in a research note on Tuesday, July 29th. They set an “outperform” rating on the stock. Finally, analysts at BTIG Research downgraded shares of Endologix from a “buy” rating to a “neutral” rating in a research note on Monday, July 7th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and four have issued a buy rating to the stock. The company has a consensus rating of “Hold” and an average target price of $17.05.

Endologix (NASDAQ:ELGX) traded down 0.71% during mid-day trading on Tuesday, hitting $13.95. The stock had a trading volume of 415,372 shares. Endologix has a 1-year low of $11.47 and a 1-year high of $18.85. The stock has a 50-day moving average of $14.50 and a 200-day moving average of $14.1. The company’s market cap is $934.0 million.

Endologix (NASDAQ:ELGX) last posted its quarterly earnings results on Wednesday, July 30th. The company reported ($0.06) earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.08) by $0.02. The company had revenue of $38.30 million for the quarter, compared to the consensus estimate of $36.50 million. During the same quarter last year, the company posted ($0.03) earnings per share. Endologix’s revenue was up 12.6% compared to the same quarter last year. Analysts expect that Endologix will post $-0.28 EPS for the current fiscal year.

Endologix, Inc (NASDAQ:ELGX) is engaged in developing, manufacturing, marketing and selling medical devices for the treatment of aortic disorders.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.